Pricing and reimbursement of drugs and medical devices in Hungary

L. Gulácsi, T. Dávid, Cs Dózsa

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

Similarly to other countries of Central and Eastern Europe, Hungary has witnessed massive diffusion of healthcare technology such as drugs and medical devices since 1990. While substantial new pharmaceuticals, medical devices, and procedures have been liberalized, there has been no proper evaluation or training in their use. Healthcare providers have come to find themselves as entrepreneurs in private practice, while patients are acquiring an increasing awareness as customers of healthcare, demanding services in return for their taxes and contributions. This has led to extremely irrational patterns of investment in technology, with most an obvious waste of resources, while leaving basic needs unmet. Both the National Health Insurance Fund and the Ministry of Finance believe that the current pharmaceutical and medical device bill is too high. However, introducing a more transparent and flexible pricing and reimbursement framework may enable a more efficient allocation of the limited resources to be achieved.

Original languageEnglish
Pages (from-to)271-278
Number of pages8
JournalEuropean Journal of Health Economics
Volume3
Issue number4
DOIs
Publication statusPublished - 2002

Fingerprint

Hungary
Costs and Cost Analysis
Equipment and Supplies
Pharmaceutical Preparations
Technology
Delivery of Health Care
Eastern Europe
Resource Allocation
Private Practice
Taxes
National Health Programs
Health Personnel
Drugs
Pricing
Reimbursement
Medical devices
Pharmaceuticals
Healthcare
Resources

Keywords

  • Healthcare expenditure
  • Healthcare financing
  • Healthcare privatization
  • Hungary
  • Pharmaceutical pricing and reimbursement

ASJC Scopus subject areas

  • Medicine (miscellaneous)

Cite this

Pricing and reimbursement of drugs and medical devices in Hungary. / Gulácsi, L.; Dávid, T.; Dózsa, Cs.

In: European Journal of Health Economics, Vol. 3, No. 4, 2002, p. 271-278.

Research output: Contribution to journalArticle

@article{cc16dfc554944991a11f3a6b26bfe028,
title = "Pricing and reimbursement of drugs and medical devices in Hungary",
abstract = "Similarly to other countries of Central and Eastern Europe, Hungary has witnessed massive diffusion of healthcare technology such as drugs and medical devices since 1990. While substantial new pharmaceuticals, medical devices, and procedures have been liberalized, there has been no proper evaluation or training in their use. Healthcare providers have come to find themselves as entrepreneurs in private practice, while patients are acquiring an increasing awareness as customers of healthcare, demanding services in return for their taxes and contributions. This has led to extremely irrational patterns of investment in technology, with most an obvious waste of resources, while leaving basic needs unmet. Both the National Health Insurance Fund and the Ministry of Finance believe that the current pharmaceutical and medical device bill is too high. However, introducing a more transparent and flexible pricing and reimbursement framework may enable a more efficient allocation of the limited resources to be achieved.",
keywords = "Healthcare expenditure, Healthcare financing, Healthcare privatization, Hungary, Pharmaceutical pricing and reimbursement",
author = "L. Gul{\'a}csi and T. D{\'a}vid and Cs D{\'o}zsa",
year = "2002",
doi = "10.1007/s10198-002-0148-z",
language = "English",
volume = "3",
pages = "271--278",
journal = "European Journal of Health Economics",
issn = "1618-7598",
publisher = "Springer Verlag",
number = "4",

}

TY - JOUR

T1 - Pricing and reimbursement of drugs and medical devices in Hungary

AU - Gulácsi, L.

AU - Dávid, T.

AU - Dózsa, Cs

PY - 2002

Y1 - 2002

N2 - Similarly to other countries of Central and Eastern Europe, Hungary has witnessed massive diffusion of healthcare technology such as drugs and medical devices since 1990. While substantial new pharmaceuticals, medical devices, and procedures have been liberalized, there has been no proper evaluation or training in their use. Healthcare providers have come to find themselves as entrepreneurs in private practice, while patients are acquiring an increasing awareness as customers of healthcare, demanding services in return for their taxes and contributions. This has led to extremely irrational patterns of investment in technology, with most an obvious waste of resources, while leaving basic needs unmet. Both the National Health Insurance Fund and the Ministry of Finance believe that the current pharmaceutical and medical device bill is too high. However, introducing a more transparent and flexible pricing and reimbursement framework may enable a more efficient allocation of the limited resources to be achieved.

AB - Similarly to other countries of Central and Eastern Europe, Hungary has witnessed massive diffusion of healthcare technology such as drugs and medical devices since 1990. While substantial new pharmaceuticals, medical devices, and procedures have been liberalized, there has been no proper evaluation or training in their use. Healthcare providers have come to find themselves as entrepreneurs in private practice, while patients are acquiring an increasing awareness as customers of healthcare, demanding services in return for their taxes and contributions. This has led to extremely irrational patterns of investment in technology, with most an obvious waste of resources, while leaving basic needs unmet. Both the National Health Insurance Fund and the Ministry of Finance believe that the current pharmaceutical and medical device bill is too high. However, introducing a more transparent and flexible pricing and reimbursement framework may enable a more efficient allocation of the limited resources to be achieved.

KW - Healthcare expenditure

KW - Healthcare financing

KW - Healthcare privatization

KW - Hungary

KW - Pharmaceutical pricing and reimbursement

UR - http://www.scopus.com/inward/record.url?scp=0036961317&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036961317&partnerID=8YFLogxK

U2 - 10.1007/s10198-002-0148-z

DO - 10.1007/s10198-002-0148-z

M3 - Article

C2 - 15609154

AN - SCOPUS:0036961317

VL - 3

SP - 271

EP - 278

JO - European Journal of Health Economics

JF - European Journal of Health Economics

SN - 1618-7598

IS - 4

ER -